Our patented aptamers have demonstrated benefits in animal models of disease. D5Pharma’s lead drug candidate is PEG:CCS13, a PEGylated single-stranded DNA aptamer that is a selective agonist for the inflammatory modulator, CD200R1, a glycoprotein receptor found on the surface of immune cells.
